Finally, trickleUp is a micro-enterprise development program targeted at those living on under $1.25/day, which provides the indigent with resources to build a sustainable livelihood through both direct financing and considerable training efforts.Oxfam is a non-governmental organization that works prominently in Africa; their mission is to improve local community organizations and it works to reduce impediments to the development of the country. Oxfam helps families suffering from poverty receive food and healthcare to survive. There are many children in Africa experiencing growth stunting, and this is one example of an issue that Oxfam targets and aims to resolve.Cash transfers appear to be an effective intervention for reducing extreme poverty, while at the same time improving health and education outcomes. Campaigns
Giving What We Can
Global Poverty Project
Live Below the Line
Make Poverty History

See also
List of countries by percentage of population living in poverty
Income inequality metrics
Least developed countries
Poverty threshold
Poverty reduction
Millennium Development Goals (2015)
Sustainable Development Goals (2030)

References
External links

Eradicate Extreme Poverty and Hunger by 2015 | UN Millennium Development Goal curated by the Center for Latin American and Caribbean Studies at Michigan State University
The Life You Can Save – Acting Now to End World Poverty
Scientific American Magazine (September 2005 Issue) Can Extreme Poverty Be Eliminated? International Movement ATD Fourth World
Walk In Her Shoes
History
The first CDG patients (twin sisters) were described in 1980 by Jaeken et al. Their main features were psychomotor retardation, cerebral and cerebellar atrophy and fluctuating hormone levels (e.g.prolactin, FSH and GH). During the next 15 years the underlying defect remained unknown but since the plasmaprotein transferrin was underglycosylated (as shown by e.g. isoelectric focusing), the new syndrome was named carbohydrate-deficient glycoprotein syndrome (CDGS) Its "classical" phenotype included psychomotor retardation, ataxia, strabismus, anomalies (fat pads and inverted nipples) and coagulopathy.In 1994, a new phenotype was described and named CDGS-II. In 1995, Van Schaftingen and Jaeken showed that CDGS-I (now PMM2-CDG) was caused by the deficiency of the enzyme phosphomannomutase. This enzyme is responsible for the interconversion of mannose-6-phosphate and mannose-1-phosphate, and its deficiency leads to a shortage in GDP-mannose and dolichol (Dol)-mannose (Man), two donors required for the synthesis of the lipid-linked oligosaccharide precursor of N-linked glycosylation.In 1998, Niehues described a new CDG syndrome, MPI-CDG, which is caused by mutations in the enzyme metabolically upstream of PMM2, phosphomannose isomerase (PMI). A functional therapy for MPI-CDG, alimentary mannose was also described. The characterization of new defects took increased and several new Type I and Type II defects were delineated.In 2012, Need described the first case of a congenital disorder of deglycosylation, NGLY1 deficiency. A 2014 study of NGLY1 deficient patients found similarities with traditional congenital disorders of glycosylation.